Galapagos NV Company Profile (NASDAQ:GLPG)

About Galapagos NV

Galapagos NV logoGalapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GLPG
  • CUSIP:
Key Metrics:
  • Previous Close: $63.30
  • 50 Day Moving Average: $57.72
  • 200 Day Moving Average: $52.14
  • 52-Week Range: €37.03 - €73.37
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 1,266.00
  • P/E Growth: 0.00
  • Market Cap: $2.92B
  • Outstanding Shares: 46,109,000
  • Beta: 2.14
Additional Links:
Companies Related to Galapagos NV:

Analyst Ratings

Consensus Ratings for Galapagos NV (NASDAQ:GLPG) (?)
Ratings Breakdown: 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: €66.25 (4.66% upside)

Analysts' Ratings History for Galapagos NV (NASDAQ:GLPG)
Show:
DateFirmActionRatingPrice TargetDetails
8/30/2016Janney Montgomery ScottInitiated CoverageBuy -> Buy$64.00View Rating Details
6/17/2016Credit Suisse Group AGReiterated RatingHold$48.00View Rating Details
5/2/2016Morgan StanleyReiterated RatingBuy$89.00View Rating Details
4/30/2016Cowen and CompanyReiterated RatingBuyView Rating Details
1/25/2016Goldman Sachs Group Inc.DowngradeBuy -> NeutralView Rating Details
12/17/2015Bryan, Garnier & CoBoost Price TargetBuy$52.00 -> $64.00View Rating Details
12/8/2015KBC SecuritiesUpgradeBuyView Rating Details
6/8/2015Credit Agricole SAInitiated CoverageOutperform$61.00View Rating Details
6/8/2015NomuraInitiated CoverageBuy$73.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Galapagos NV (NASDAQ:GLPG)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Galapagos NV (NASDAQ:GLPG)
Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $0.05 EPS

Dividends

Dividend History for Galapagos NV (NASDAQ:GLPG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galapagos NV (NASDAQ:GLPG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Galapagos NV (NASDAQ:GLPG)
DateHeadline
globenewswire.com logoMorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis - GlobeNewswire (press release) (NASDAQ:GLPG)
globenewswire.com - September 29 at 5:09 PM
investopedia.com logoGilead May Not Acquire Galapagos, For Now (GILD, GLPG) - Investopedia (NASDAQ:GLPG)
www.investopedia.com - September 29 at 5:09 PM
investingnews.com logoMorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 (NASDAQ:GLPG)
investingnews.com - September 29 at 10:15 AM
publicnow.com logoMorphoSys and Galapagos start first-in-patient dosing of IL-17C antibody MOR106 in atopic dermatitis (NASDAQ:GLPG)
www.publicnow.com - September 29 at 10:15 AM
kcregister.com logoWhy Need to Watch: Medivation, Inc. (NASDAQ:MDVN), Galapagos NV (NASDAQ:GLPG), Golub Capital BDC, Inc ... - KC Register (NASDAQ:GLPG)
www.kcregister.com - September 28 at 5:02 PM
streetinsider.com logoGalapagos NV (GLPG) Says Regulatory Discussions Over DIVERSITY Phase 3 Completed - StreetInsider.com (NASDAQ:GLPG)
www.streetinsider.com - September 28 at 5:02 PM
streetinsider.com logoGalapagos NV (GLPG) Says Regulatory Discussions Over DIVERSITY Phase 3 Completed (NASDAQ:GLPG)
www.streetinsider.com - September 28 at 10:07 AM
publicnow.com logoSuccessful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease (NASDAQ:GLPG)
www.publicnow.com - September 27 at 5:16 PM
4-traders.com logoGalapagos : increases share capital through warrant exercises (NASDAQ:GLPG)
www.4-traders.com - September 27 at 9:48 AM
publicnow.com logoEndoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease (NASDAQ:GLPG)
www.publicnow.com - September 26 at 9:56 AM
News IconGalapagos NV (ADR) Can't Burn Your Long Portfolio. Just Reaches All-Time High - Post News (NASDAQ:GLPG)
www.kentuckypostnews.com - September 25 at 4:46 PM
investing.com logoNetherlands stocks lower at close of trade; AEX down 0.23% (NASDAQ:GLPG)
www.investing.com - September 24 at 9:48 AM
News IconShares Recorded Gapping Higher Pre-Market: Galapagos NV (NASDAQ:GLPG) - Post News (NASDAQ:GLPG)
www.kentuckypostnews.com - September 23 at 10:14 AM
News IconCelebrate This High-Profit Milestone with Some More Triple-Digit Gains (NASDAQ:GLPG)
moneymorning.com - September 22 at 5:20 PM
News IconGalapagos NV (NASDAQ: GLPG) stock bounces off 52-week high - The Woodbridge Citizen (NASDAQ:GLPG)
www.woodbridgecitizen.com - September 21 at 5:42 PM
kcregister.com logoToday's Stocks: Galapagos NV (NASDAQ:GLPG), Merck & Co., Inc. (NYSE:MRK), Alphabet Inc (NASDAQ:GOOG ... - KC Register (NASDAQ:GLPG)
www.kcregister.com - September 21 at 5:42 PM
News IconGalapagos NV (ADR) (NASDAQ:GLPG) reports the initiation of the FINCH global Phase 3 program investigating the ... - Inside Trade (NASDAQ:GLPG)
insidetrade.co - September 21 at 5:42 PM
investing.com logoBelgium stocks higher at close of trade; BEL 20 up 0.13% (NASDAQ:GLPG)
www.investing.com - September 21 at 9:29 AM
finanznachrichten.de logoGalapagos NV: Galapagos increases share capital through warrant exercises (NASDAQ:GLPG)
www.finanznachrichten.de - September 21 at 9:29 AM
News IconGalapagos NV (ADR) (NASDAQ:GLPG) reports the initiation of the FINCH global Phase 3 program investigating the efficacy and safety of 100 mg (NASDAQ:GLPG)
insidetrade.co - September 21 at 9:29 AM
News IconShares Observed Gapping Up Before Market Open: Galapagos NV (NASDAQ:GLPG) - Post News (NASDAQ:GLPG)
www.kentuckypostnews.com - September 20 at 10:23 AM
investing.com logoBelgium stocks higher at close of trade; BEL 20 up 0.77% - Investing.com (NASDAQ:GLPG)
www.investing.com - September 19 at 5:22 PM
investing.com logoNetherlands stocks higher at close of trade; AEX up 1.28% - Investing.com (NASDAQ:GLPG)
www.investing.com - September 19 at 5:22 PM
streetinsider.com logoGalapagos NV (GLPG) Announces Share Capital Increase - StreetInsider.com (NASDAQ:GLPG)
www.streetinsider.com - September 19 at 5:22 PM
finance.yahoo.com logoGalapagos increases share capital through warrant exercises (NASDAQ:GLPG)
finance.yahoo.com - September 19 at 5:22 PM
investing.com logoNetherlands shares lower at close of trade; AEX down 0.93% - Investing.com UK (NASDAQ:GLPG)
uk.investing.com - September 17 at 4:59 PM
investing.com logoBelgium stocks lower at close of trade; BEL 20 down 0.38% - Investing.com (NASDAQ:GLPG)
www.investing.com - September 17 at 4:59 PM
investing.com logoNetherlands stocks lower at close of trade; AEX down 0.93% - Investing.com (NASDAQ:GLPG)
www.investing.com - September 16 at 5:04 PM
investing.com logoBelgium shares lower at close of trade; BEL 20 down 0.38% By ... - Investing.com UK (NASDAQ:GLPG)
uk.investing.com - September 16 at 5:04 PM
investing.com logoNetherlands stocks higher at close of trade; AEX up 0.49% - Investing.com (NASDAQ:GLPG)
www.investing.com - September 16 at 9:04 AM
barrons.com logoVertex Looks to Cash In On Its Rich Drug Pipeline - Barron's (NASDAQ:GLPG)
www.barrons.com - September 16 at 9:04 AM
investing.com logoBelgium stocks higher at close of trade; BEL 20 up 0.57% By ... - Investing.com (NASDAQ:GLPG)
www.investing.com - September 15 at 5:36 PM
capitalcube.com logoETF’s with exposure to Galapagos NV : September 15, 2016 (NASDAQ:GLPG)
www.capitalcube.com - September 15 at 5:36 PM
investing.com logoNetherlands stocks lower at close of trade; AEX down 0.36% By ... - Investing.com (NASDAQ:GLPG)
www.investing.com - September 15 at 8:19 AM
seekingalpha.com logoGalapagos Remains A Long-Term Buy In Biotech (NASDAQ:GLPG)
seekingalpha.com - September 12 at 10:02 AM
seekingalpha.com logoGalapagos Remains A Long-Term Buy In Biotech - Seeking Alpha (NASDAQ:GLPG)
seekingalpha.com - September 11 at 4:53 PM
investing.com logoBelgium stocks lower at close of trade; BEL 20 down 1.07% By ... - Investing.com (NASDAQ:GLPG)
www.investing.com - September 11 at 9:37 AM
investing.com logoBelgium shares lower at close of trade; BEL 20 down 1.07% By ... - Investing.com UK (NASDAQ:GLPG)
uk.investing.com - September 10 at 9:44 AM
News IconAnalysts Take the Wheel on Galapagos NV (ADR) (NASDAQ:GLPG) Shares and Where They Might Be Headed - Frisco Fastball (NASDAQ:GLPG)
friscofastball.com - September 10 at 9:44 AM
nasdaq.com logoGalapagos: EC Grants GLPG1690 Orphan Drug Designation To Treat IPF Patients (NASDAQ:GLPG)
www.nasdaq.com - September 7 at 8:40 AM
finanznachrichten.de logoGalapagos NV: Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis (NASDAQ:GLPG)
www.finanznachrichten.de - September 7 at 8:40 AM
investing.com logoBelgium shares lower at close of trade; BEL 20 down 0.21% By ... - Investing.com UK (NASDAQ:GLPG)
uk.investing.com - September 6 at 5:17 PM
investing.com logoNetherlands shares lower at close of trade; AEX down 0.65% - Investing.com UK (NASDAQ:GLPG)
uk.investing.com - September 6 at 5:17 PM
investing.com logoBelgium stocks higher at close of trade; BEL 20 up 0.13% - Investing.com (NASDAQ:GLPG)
www.investing.com - September 6 at 9:59 AM
News IconGilead Sciences Inc.'s 5 Best Moves in 2016 So Far - Madison.com (NASDAQ:GLPG)
host.madison.com - September 6 at 9:59 AM
streetinsider.com logoGalapagos (GLPG) Receives European Commission Orphan Drug Designation for GLPG1690 as IPF Treatment - StreetInsider.com (NASDAQ:GLPG)
www.streetinsider.com - September 6 at 9:59 AM
publicnow.com logoOrphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis (NASDAQ:GLPG)
www.publicnow.com - September 6 at 9:59 AM
finance.yahoo.com logo4:31 am Galapagos receives Orphan Drug designation in the EU for GLPG1690 (NASDAQ:GLPG)
finance.yahoo.com - September 6 at 9:59 AM
fool.com logoGilead Sciences Inc.'s 5 Best Moves in 2016 So Far - Motley Fool (NASDAQ:GLPG)
www.fool.com - September 5 at 9:43 AM
seekingalpha.com logoHealthcare ratings roundup - new coverage - Seeking Alpha (NASDAQ:GLPG)
seekingalpha.com - September 2 at 5:09 PM

Social

Galapagos NV (NASDAQ:GLPG) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff